Corticosteroid

Anterior Uveitis Treatment Market Size Worth $418.23 Million By 2026: Grand View Research, Inc.

Retrieved on: 
星期三, 九月 18, 2019
Medical specialties, Medicine, Uveitis, Clinical medicine, Intermediate uveitis, Corticosteroid

SAN FRANCISCO, Sept. 18, 2019 /PRNewswire/ -- The global anterior uveitis treatment market size is expected to reach USD 418.23 million by 2026, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 5.4%.

Key Points: 
  • SAN FRANCISCO, Sept. 18, 2019 /PRNewswire/ -- The global anterior uveitis treatment market size is expected to reach USD 418.23 million by 2026, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 5.4%.
  • This disease is more common when compared to panuveitis, posterior, and intermediate uveitis.
  • Key suggestions from the report:
    Corticosteroids dominated the anterior uveitis treatment market in 2018 owing to its beneficial characteristic of minimizing inflammation in the eye.
  • Grand View Research has segmented the anterior uveitis treatment market on the basis of treatment type, distribution channel, and region:
    Anterior Uveitis Treatment Type Outlook (Revenue, USD Million, 2015 - 2026)

Anterior Uveitis Treatment Market Size Worth $418.23 Million By 2026: Grand View Research, Inc.

Retrieved on: 
星期三, 九月 18, 2019
Medical specialties, Medicine, Uveitis, Clinical medicine, Intermediate uveitis, Corticosteroid

SAN FRANCISCO, Sept. 18, 2019 /PRNewswire/ -- The global anterior uveitis treatment market size is expected to reach USD 418.23 million by 2026, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 5.4%.

Key Points: 
  • SAN FRANCISCO, Sept. 18, 2019 /PRNewswire/ -- The global anterior uveitis treatment market size is expected to reach USD 418.23 million by 2026, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 5.4%.
  • This disease is more common when compared to panuveitis, posterior, and intermediate uveitis.
  • Key suggestions from the report:
    Corticosteroids dominated the anterior uveitis treatment market in 2018 owing to its beneficial characteristic of minimizing inflammation in the eye.
  • Grand View Research has segmented the anterior uveitis treatment market on the basis of treatment type, distribution channel, and region:
    Anterior Uveitis Treatment Type Outlook (Revenue, USD Million, 2015 - 2026)

EyePoint Pharmaceuticals, Inc. - U.S. Commercialization of DEXYCU® (dexamethasone intraocular suspension) 9%

Retrieved on: 
星期一, 七月 8, 2019
Medical specialties, Medicine, Ophthalmology, Eye, Keratitis, Corneal ulcer, Herpes simplex keratitis, Uveitis, Corticosteroid, Sclera, Red eye, Corneal ulcers in animals

Prolonged use of corticosteroids, including DEXYCU, may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision

Key Points: 
  • Prolonged use of corticosteroids, including DEXYCU, may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision
    In those diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of corticosteroids
    The use of DEXYCU, as with other ophthalmic corticosteroids, is not recommended in the presence of most active viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal disease of ocular structures
    Fungal infections of the cornea are particularly prone to coincidentally develop with long-term local steroid application and must be considered in any persistent corneal ulceration where a steroid has been used or is in use.
  • Fungal culture should be taken when appropriate
    Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infections.
  • In acute purulent conditions, steroids may mask infection or enhance existing infection
    The most commonly reported adverse reactions occurred in 5-15% of subjects and included increases in intraocular pressure, corneal edema and iritis
    Link to the full Prescribing Information:
    DEXYCU is a registered trademark and the EyePoint logo is a trademark of EyePoint Pharmaceuticals, Inc.
    Verisome is a registered trademark of Ramscor, Inc.

FDA approves first treatment for chronic rhinosinusitis with nasal polyps

Retrieved on: 
星期三, 六月 26, 2019
Medicine, Clinical medicine, Health, RTT, Nasal polyp, Sinusitis, Nasal administration, Polyp, Nasal congestion, Corticosteroid, Dupilumab, Nonallergic rhinitis

This is the first treatment approved for inadequately controlled chronic rhinosinusis with nasal polyps.

Key Points: 
  • This is the first treatment approved for inadequately controlled chronic rhinosinusis with nasal polyps.
  • "Dupixent provides an important treatment option for patients whose nasal polyps are not adequately controlled with intranasal steroids.
  • The efficacy and safety of Dupixent were established intwo studies with 724 patients, 18 years and older with chronic rhinosinusitis with nasal polyps who were symptomatic despite taking intranasal corticosteroids.
  • Patients who received Dupixent had statistically significant reductions in their nasal polyp size and nasal congestion compared to the placebo group.

Phase III PEMPHIX Study Showed That Genentech’s Rituxan (Rituximab) is Superior to Standard of Care in Achieving Sustained Remission in Patients with Pemphigus Vulgaris

Retrieved on: 
星期四, 六月 13, 2019
Health, Biotechnology, Clinical trials, Pharmaceutical, FDA, Medicine, Health, Clinical medicine, Autoimmune diseases, RTT, Genentech, Rare diseases, Rituximab, Pemphigus vulgaris, Corticosteroid, Clinical endpoint, Pemphigus

The study met the primary endpoint, and demonstrated that Rituxan is superior to MMF in achieving sustained complete remission.

Key Points: 
  • The study met the primary endpoint, and demonstrated that Rituxan is superior to MMF in achieving sustained complete remission.
  • These data also demonstrated that Rituxan may provide complete remission rates and successful tapering of corticosteroid therapy that is superior to MMF in adults with pemphigus vulgaris.
  • Rituxan also met the secondary endpoints, including cumulative corticosteroid dose, number of flares, time to sustained remission and time to disease flare.
  • Adverse events were generally consistent with those seen in previous Rituxan clinical studies for other autoimmune indications.

Global Uveitis Drugs Market to Grow by USD 452.87 Million During 2019-2023 | Technavio

Retrieved on: 
星期五, 六月 7, 2019
Health, Pharmaceutical, Medical specialties, Medicine, Endocrine system, Uveitis, Corticosteroid

Technavios latest market research report on the global uveitis drugs market predicts the market to witness a CAGR of close to 7% during the forecast period.

Key Points: 
  • Technavios latest market research report on the global uveitis drugs market predicts the market to witness a CAGR of close to 7% during the forecast period.
  • View the full release here: https://www.businesswire.com/news/home/20190607005242/en/
    Technavio has published a new market research report on the global uveitis drugs market from 2019-2023.
  • The small molecules segment is expected to garner the highest uveitis drugs market share mainly due to the increased use of corticosteroids for the treatment of uveitis.
  • Some of the key topics covered in the global uveitis drugs market analysis include:

FDA Approves Jakafi® (ruxolitinib) for the Treatment of Patients with Acute Graft-Versus-Host Disease

Retrieved on: 
星期五, 五月 24, 2019
Stem cells, Health, Clinical trials, Infectious diseases, Pharmaceutical, Other Health, FDA, General Health, Chemical compounds, Medical specialties, Medicine, Transplantation medicine, Immune system disorders, Incyte, Graft-versus-host disease, Pyrazoles, Ruxolitinib, Corticosteroid, Janus kinase inhibitor

For the first time, patients with steroid-refractory acute GVHD, and the physicians that treat them, have an FDA-approved treatment for this serious disease, stated Herv Hoppenot, Chief Executive Officer, Incyte.

Key Points: 
  • For the first time, patients with steroid-refractory acute GVHD, and the physicians that treat them, have an FDA-approved treatment for this serious disease, stated Herv Hoppenot, Chief Executive Officer, Incyte.
  • The approval was based on data from REACH1, an open-label, single-arm, multicenter study of Jakafi in combination with corticosteroids in patients with steroid-refractory grade II-IV acute GVHD.
  • I am excited that we now have Jakafi as a new treatment option for acute GVHD patients that do not respond to corticosteroids who, until now, have had limited choices.
  • Jakafi is a first-in-class JAK1/JAK2 inhibitor approved by the U.S. FDA for treatment of steroid-refractory acute GVHD in adult and pediatric patients 12 years and older.

New Data Highlights the Value of SPRAVATO™ (esketamine) CIII Nasal Spray, the First New Antidepressant in Decades that Works Differently for Adults with Treatment-Resistant Depression (TRD)[1]

Retrieved on: 
星期二, 五月 21, 2019
Psychoactive drugs, Medicine, Drugs, Depression, Amines, Dosage forms, Esketamine, Nasal spray, Medication, Decongestant, Antidepressant, Corticosteroid

Click to Tweet: #BREAKING: New cost-efficiency data presented at #ISPOR2019 highlights the value of SPRAVATO (esketamine) CIII nasal spray for patients, payers, and society.

Key Points: 
  • Click to Tweet: #BREAKING: New cost-efficiency data presented at #ISPOR2019 highlights the value of SPRAVATO (esketamine) CIII nasal spray for patients, payers, and society.
  • Janssen also offers a comprehensive support program that helps patients get started on SPRAVATO and stay on track.
  • SPRAVATO is a prescription medicine, used along with an antidepressant taken by mouth, for treatment-resistant depression (TRD) in adults.
  • If you take a nasal corticosteroid or nasal decongestant medicine, take these medicines at least 1 hour before taking SPRAVATO.

Dupixent® (dupilumab) Approved for Severe Asthma by European Commission

Retrieved on: 
星期二, 五月 7, 2019
Respiratory therapy, Medicine, Health, Dupilumab, Asthma, Exhaled nitric oxide, Corticosteroid, Spirometry, Eosinophilic bronchitis

Only biologic approved in the EU for severe asthma with type 2 inflammation, as characterized by raised blood eosinophils and/or raised fractional exhaled nitric oxide (FeNO)

Key Points: 
  • Only biologic approved in the EU for severe asthma with type 2 inflammation, as characterized by raised blood eosinophils and/or raised fractional exhaled nitric oxide (FeNO)
    In clinical trials, Dupixent improved lung function and quality of life, and reduced severe exacerbations and oral corticosteroid use
    Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Commission (EC) approved a new indication for Dupixent (dupilumab) in asthma.
  • QUEST enrolled 1,902 patients with persistent asthma and evaluated whether adding Dupixent to standard-of-care therapy could reduce severe exacerbations and improve lung function (measured by FEV1).
  • VENTURE enrolled 210 patients with severe oral corticosteroid-dependent asthma and evaluated whether adding Dupixent to standard-of-care therapy could reduce the use of maintenance oral corticosteroids.
  • DUPIXENT may also help reduce the amount of oral corticosteroids you need while preventing severe asthma attacks and improving your breathing.

Chronic Obstructive Pulmonary Disease Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 -2026

Retrieved on: 
星期四, 四月 11, 2019
Medicine, Drugs, Pulmonology, Respiratory therapy, Combination drugs, Chronic lower respiratory diseases, Chronic obstructive pulmonary disease, Long-acting beta-adrenoceptor agonist, Bronchodilator, Corticosteroid, Obstructive lung disease, Revefenacin

Global Chronic Obstructive Pulmonary Disease Treatment Market: Overview

Key Points: 
  • Global Chronic Obstructive Pulmonary Disease Treatment Market: Overview
    This report analyzes the current and future scenario of the global chronic obstructive pulmonary disease (COPD) treatment market.Rise in prevalence of COPD, increase in the adoption of combination therapy, and surge in awareness about COPD treatment are the key factors anticipated to drive the global market.
  • This section of the report also provides market attractiveness analysis by region and market share analysis by key players, thereby presenting a thorough analysis of the overall competitive scenario in the global chronic obstructive pulmonary disease treatment market.
  • Global Chronic Obstructive Pulmonary Disease Treatment Market: Key Segments
    In terms of drug class, the global chronic obstructive pulmonary disease treatment market has been segmented into combination, bronchodilators, corticosteroids, phosphodiesterase type 4 inhibitors, mucokineticsm and others.The combination segment has been divided into long acting muscarinic antagonist & inhaled corticosteroids (LAMA-ICS), long acting beta agonist & inhaled corticosteroids (LABA-ICS), triple therapy, and others.
  • The global chronic obstructive pulmonary disease treatment market has been segmented as below:
    Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, by Drug Class